Circulating interleukin-6 predicts survival in patients with metastatic breast cancer
Circulating interleukin-6 predicts survival in patients with metastatic breast cancer
复制标题
DOI：
10.1002/ijc.10833
复制
发表时间：
2003-02-20
影响因子：
6.4
通讯作者：
Dirix, LY
中科院分区：
文献类型：
--
作者：
Salgado, R;Junius, S;Dirix, LY
白介素6-(IL-6)是由巨噬细胞、T细胞、B细胞、内皮细胞和肿瘤细胞产生的多功能细胞因子。 Interleukin-6 能够通过上调肿瘤细胞中的抗凋亡蛋白和血管生成蛋白来促进肿瘤生长。在小鼠模型中，已证明抗 IL-6 抗体可抑制肿瘤生长。一些报告强调了 IL-6 在前列腺癌和结肠癌等疾病中的预后重要性。我们前瞻性地探讨了在开始全身治疗前的 96 名未经选择的连续进展性转移性乳腺癌患者中诊断转移时测量的血清 IL-6 (sIL-6) 的预后意义。乳腺癌人群的 sIL-6 中位值为 6.6 +/- 2.1 pg/ml。与仅具有 1 个转移部位的患者相比，具有 2 个或更多转移部位的患者具有更高的 sIL-6 值（分别为 8.15 +/- 1.7 pg/ml 和 3.06 +/- 6.6 pg/ml；p < 0.001）。肝转移 (8.3 +/- 2.4 pg/ml)、胸腔积液 (10.65 +/- 9.9 pg/ml) 和主要内脏疾病 (8.15 +/- 3.3 pg/ml) 的患者的值显着高于无肝转移 (4.5 +/- 3.4 pg/ml; p < 0.001)、无胸腔积液的患者（5.45 +/- 1.5皮克/毫升； p = 0.0077）和显性骨病（4.5 +/- 1.4 pg/ml；p = 0.007）。未发现 sIL-6 与年龄、绝经状态、体能状态、肿瘤分级、体重指数、组织学和激素受体状态之间存在相关性。多变量分析显示血清IL-6水平高具有独立的预后价值。我们得出的结论是，循环中的 IL-6 与转移性乳腺癌患者的生存率较差有关，并且与疾病的程度相关。 (C) 2002 Wiley-Liss, Inc.
Interleukin-6-(IL-6) is a multifunctional cytokine produced by macrophages, T cells, B cells, enclothelial cells and tumour cells. Interleukin-6 is able to promote tumour growth by upregulating anti-apoptotic and angiogenic proteins in tumour cells. In murine models it has been demonstrated that antibodies against IL-6 diminish tumour growth. Several reports have highlighted the prognostic importance of IL-6 in e.g., prostate and colon cancer. We addressed prospectively the prognostic significance of serum IL-6 (sIL-6), measured at diagnosis of metastasis, in 96 unselected and consecutive patients with progressive metastatic breast cancer before the initiation of systemic therapy. The median sIL-6 value for the breast cancer population was 6.6 +/- 2.1 pg/ml. Patients with 2 or more metastatic sites had higher sIL-6 values compared to those with only I metastatic site (respectively 8.15 +/- 1.7 pg/ml and 3.06 +/- 6.6 pg/ml; p < 0.001). Patients with liver metastasis (8.3 +/- 2.4 pg/ml), with pleural effusions (10.65 +/- 9.9 pg/ml) and with dominant visceral disease (8.15 +/- 3.3. pg/ml) had significantly higher values compared to those without liver metastases (4.5 +/- 3.4 pg/ml; p 0.001), without pleural effusions (5.45 +/- 1.5 pg/ml; p = 0.0077) and with dominant bone disease (4.5 +/- 1.4 pg/ml; p = 0.007) respectively. No correlation between sIL-6 and age, menopausal status, performance status, tumour grade, body-mass index, histology and hormone receptor status was found. Multivariate analysis showed that high levels of serum IL-6 have independent prognostic value. We conclude that circulating IL-6 is associated with worse survival in patients with metastatic breast cancer and is correlated with the extent of disease. (C) 2002 Wiley-Liss, Inc.